OACC logo

OAKTREE ACQUISITION CORP I-A

OACCNASDAQ
🏆 #3502 by market capUS Equity
$157.35▲ $5.66 (+3.60%)
Simulated price
🔔
Track OACC
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 3.6%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$264M
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
84
Good
No chart data available for OACC.

Trading Snapshot

Day Range
$156.18 – $160.42
52-Week Range
$10.45 – $10.88
Volume
$4.00B
Avg Volume
$3.61B
Shares Outstanding
24.6M
Next Earnings
Dec 7, 2026

Fundamentals Snapshot

Annual Revenue
$50M
Last Q Revenue
$14M
P/E Ratio
38.0
P/S Ratio
0.0x
EPS (TTM)
$0.35
Dividend Yield
0.00%
Dilution (1yr)
+0.0%

Why Investors Own OACC

  • ✓High-growth profile — revenue up +3.5% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 78% gross margin and 8% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

OACC logo

OAKTREE ACQUISITION CORP I-A

OACC
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$1M▲ +169983.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$422K▲ +235698.3% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
24.6M▲ +0.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$1M▲ +$78K YoY
StockOtter · stockotter.space

About OAKTREE ACQUISITION CORP I-A

Oaktree Acquisition Corp. III Life Sciences does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. It intends to target companies in the biopharmaceutical, medical devices, diagnostics, and specialized healthcare services sectors in North America and Europe. The company was incorporated in 2024 and is based in Los Angeles, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Good
84/100

Analyst Price Target

ⓘ
Average Target
$175.61
▲ +11.6% Upside
High Target$205.15
Low Target$133.26
Based on 30 analysts

Latest News & Updates

🚀
CNBC·2h ago

OAKTREE ACQUISITION CORP I-A tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Bloomberg·5h ago

Analysts lift OACC price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Reuters·1d ago

OAKTREE ACQUISITION CORP I-A announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.